A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.

[1]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[2]  R. Malley,et al.  Next generation pneumococcal vaccines. , 2011, Current opinion in immunology.

[3]  S. Szu,et al.  The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant Vaccines , 2011, Clinical and Vaccine Immunology.

[4]  Todd M. Gierahn,et al.  T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. , 2011, Cell host & microbe.

[5]  C. Hale,et al.  Evaluation of the Immunogenicity and Biological Activity of the Citrobacter freundii Vi-CRM197 Conjugate as a Vaccine for Salmonella enterica Serovar Typhi , 2011, Clinical and Vaccine Immunology.

[6]  R. Rappuoli,et al.  Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. , 2011, Vaccine.

[7]  S. Winter,et al.  The Vi Capsular Polysaccharide Prevents Complement Receptor 3-Mediated Clearance of Salmonella enterica Serotype Typhi , 2010, Infection and Immunity.

[8]  S. Sayeed,et al.  GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. , 2010, Vaccine.

[9]  K. O'Brien,et al.  Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project , 2010, PLoS medicine.

[10]  G. Tyrrell,et al.  Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. , 2010, Vaccine.

[11]  R. Malley,et al.  Options for Inactivation, Adjuvant, and Route of Topical Administration of a Killed, Unencapsulated Pneumococcal Whole-Cell Vaccine , 2010, Clinical and Vaccine Immunology.

[12]  J. Villena,et al.  Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis‐PppA induces effective protection against pneumoccocal infection in young mice , 2010, Clinical and experimental immunology.

[13]  M. Molyneux,et al.  Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans , 2010, Proceedings of the National Academy of Sciences.

[14]  R. Malley.  Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development , 2010, Journal of Molecular Medicine.

[15]  C. Czerkinsky,et al.  Physical and Chemical Characterization and Immunologic Properties of Salmonella enterica Serovar Typhi Capsular Polysaccharide-Diphtheria Toxoid Conjugates , 2009, Clinical and Vaccine Immunology.

[16]  R. Prymula,et al.  10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™ , 2009, Expert review of vaccines.

[17]  T. Cherian,et al.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates , 2009, The Lancet.

[18]  Thomas B. Clarke,et al.  Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. , 2009, The Journal of clinical investigation.

[19]  R. Malley,et al.  Protection against Pneumococcal Colonization and Fatal Pneumonia by a Trivalent Conjugate of a Fusion Protein with the Cell Wall Polysaccharide , 2009, Infection and Immunity.

[20]  N. Shah.  Indian conjugate Vi typhoid vaccine: do we have enough evidence? , 2009, Indian pediatrics.

[21]  M. Lipsitch,et al.  Interleukin-17A Mediates Acquired Immunity to Pneumococcal Colonization , 2008, PLoS pathogens.

[22]  P. van Damme,et al.  Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). , 2007, Vaccine.

[23]  S. Clare,et al.  Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis. , 2006, Vaccine.

[24]  M. Lipsitch,et al.  Antibody-Independent, Interleukin-17A-Mediated, Cross-Serotype Immunity to Pneumococci in Mice Immunized Intranasally with the Cell Wall Polysaccharide , 2006, Infection and Immunity.

[25]  A. Bäumler,et al.  Capsule-Mediated Immune Evasion: a New Hypothesis Explaining Aspects of Typhoid Fever Pathogenesis , 2006, Infection and Immunity.

[26]  S. S. Tai.  Streptococcus pneumoniae Protein Vaccine Candidates: Properties, Activities and Animal Studies , 2006, Critical reviews in microbiology.

[27]  J. Weiser,et al.  Host and Bacterial Factors Contributing to the Clearance of Colonization by Streptococcus pneumoniae in a Murine Model , 2005, Infection and Immunity.

[28]  M. Lipsitch,et al.  CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Green,et al.  PppA, a Surface-Exposed Protein of Streptococcus pneumoniae, Elicits Cross-Reactive Antibodies That Reduce Colonization in a Murine Intranasal Immunization and Challenge Model , 2005, Infection and Immunity.

[30]  V. Chalifa-Caspi,et al.  Glycolytic enzymes associated with the cell surface of Streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse , 2004, Clinical and experimental immunology.

[31]  J. Crump,et al.  The global burden of typhoid fever. , 2004, Bulletin of the World Health Organization.

[32]  S. Szu,et al.  Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. , 2003, The New England journal of medicine.

[33]  E. Swiatlo,et al.  Novel vaccine strategies with protein antigens of Streptococcus pneumoniae. , 2003, FEMS immunology and medical microbiology.

[34]  M. G. Iniesta,et al.  Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers. , 2003, Vaccine.

[35]  M. Lipsitch,et al.  Intranasal Immunization with Killed Unencapsulated Whole Cells Prevents Colonization and Invasive Disease by Capsulated Pneumococci , 2001, Infection and Immunity.

[36]  J. Shiloach,et al.  The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. , 2001, The New England journal of medicine.

[37]  D. D. Trach,et al.  The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. , 2000, The American journal of tropical medicine and hygiene.

[38]  D. Briles,et al.  The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. , 2000, Vaccine.

[39]  P. Jansson,et al.  The pneumococcal common antigen C-polysaccharide occurs in different forms. Mono-substituted or di-substituted with phosphocholine. , 1999, European journal of biochemistry.

[40]  D. D. Trach,et al.  Safety and Immunogenicity of Vi Conjugate Vaccines for Typhoid Fever in Adults, Teenagers, and 2- to 4-Year-Old Children in Vietnam , 1999, Infection and Immunity.

[41]  M. Levine,et al.  Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. , 1999, Vaccine.

[42]  B. Singh,et al.  Typhoid fever in children aged less than 5 years , 1999, The Lancet.

[43]  J. Shiloach,et al.  Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines , 1994, Infection and immunity.

[44]  M. Levine,et al.  Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial , 1990, The Lancet.

[45]  S. Szu,et al.  Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi , 1989, Infection and immunity.

[46]  S. Szu,et al.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals , 1987, The Journal of experimental medicine.

[47]  J. Robbins,et al.  Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. , 1984, The Journal of infectious diseases.

[48]  D. Briles,et al.  Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate. , 1983, Journal of immunology.

[49]  D. Briles,et al.  Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody , 1982, Infection and immunity.

[50]  D. Briles,et al.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae , 1981, The Journal of experimental medicine.

[51]  S. Hestrin.  The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. , 1949, The Journal of biological chemistry.

[52]  S. Zhang,et al.  Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. , 2001, Bulletin of the World Health Organization.

[53]  J. Bonnefoy,et al.  Physico-chemical characterization and immunogenicity studies of peptide and polysaccharide conjugate vaccines based on a promising new carrier protein, the recombinant Klebsiella pneumoniae OmpA. , 2000, Developments in biologicals.

[54]  J. H. Roe.  The determination of sugar in blood and spinal fluid with anthrone reagent. , 1955, The Journal of biological chemistry.